Clinical Trial Update: Tazemetostat Plus CHOP in 1L T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tazemetostat in combination with CHOP for first-line T-cell lymphomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Tazverik (tazemetostat) (tazemetostat)
• Vincristine (vincristine)

Snippet

Sponsor: Eric Jacobsen, MD | Conditions: Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Status: WITHDRAWN